ReviewLab on a chip2025
Transforming microfluidics for single-cell analysis with robotics and artificial intelligence.
Review in Lab on a chip, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Review
- Engineering the Healing Process: Advanced In Vitro Wound Models and Technologies.Biomedicines · 2026Review
- AI and Microfluidics: Unlocking Cellular Motility for Bioengineering.Bioengineering (Basel, Switzerland) · 2026Review
- Research advances in the application of microfluidic chip technology for rapid detection of antibiotic-resistant bacteria.Frontiers in cellular and infection microbiology · 2026Review
- Microfluidics and molecular diagnostics in renal cell carcinoma: advances, challenges, and future directions.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Single-cell analysis has advanced biomedical research by revealing cellular heterogeneity with unprecedented resolution, identifying rare subpopulations that drive disease progression and therapeutic resistance. Microfluidics is central to this advancement, enabling precise single-cell isolation, manipulation, and cellular profiling. However, limitations in automation, reliability, and technical barriers hinder the widespread adoption of microfluidic single-cell analysis. This review highlights key innovations in experimental methods and deep learning-driven data analysis to overcome these challenges. Operating microfluidics with robotic operation, digital microfluidics, or microrobots enhances experimental precision and scalability. Beyond experimental automation, deep learning revolutionizes data interpretation through label-free image processing and cell status classification and regression. Generative models further refine analysis by correcting batch effects and generating synthetic datasets, improving accuracy and reproducibility in single-cell studies. Considering the complexity of integrating these technologies, remote shared cloud labs represent a potential pathway toward standardized and high-throughput single-cell analysis, facilitating broader access to advanced experimental workflows. Overall, the convergence of robotics and artificial intelligence in single-cell analysis will change data acquisition, hypothesis testing, and model refinement, driving breakthroughs in drug discovery and personalized medicine. While implementation remains challenging, this paradigm shift is transforming biomedical research, enabling unprecedented precision, scalability, and data-driven innovation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.